Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 2Propranolol 2talimogene laherparepvec 1sargramostim 1romiplostim 1propranolol CR 1imisopasem manganese 1dabrafenib 1cobimetinib 1aldesleukin 1Vemurafenib 1Vaccines 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Paclitaxel 1Nivolumab 1Nanoparticles 1Ketones 1Interleukin-2 1Glucose 1Diet Therapy 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Melanoma × propranolol CR × Clear all
NCT03384836 2025-07-02

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Roswell Park Cancer Institute

Phase 1/2 Suspended
47 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡